UpFront Collaborates with Solanic for Industrial Chromatography Installation
News Feb 08, 2007
UpFront Chromatography A/S has announced collaboration with Solanic for the installation of a Rhobust™ industrial production plant for the extraction of high-quality functional proteins from the side-stream of potato starch production.
Solanic is a business unit of AVEBE. The installation can process over 100,000 litres of raw material each day and is part of a larger project ultimately planned to extract even more than 10,000 tonnes per year of high value functional proteins for use in food and healthcare. The project will be the world’s biggest industrial protein chromatography installation by far.
The Rhobust universal processing platform, from UpFront, can capture, extract and purify functional biomolecules directly from bioreactors and industrial side-streams.
Rhobust can enable excellent process control and direct scalability. Through development of customised adsorbents and selection of appropriate ligand chemistry Rhobust has exceeded all agreed objectives with respect to yield, purity and quality within the required production goals, set by AVEBE.
“The success of the pilot study has reinforced our commitment to this technology” commented Marco Giuseppin, CTO of Solanic.
“The level of technical support and service provided by UpFront was one of the pillars for successful adoption in our industry and we look forward to developing this project into the future.”
“The success of this project is further proof of the suitability of our system to industrial scale”, commented Anders Weber, CEO of UpFront Chromatography.
“The applications for Rhobust are substantial and growing, having been implemented in a diverse range of raw materials including fermentation broths, whey, egg white and human plasma. Our Rhobust technology is already used in the world’s largest adsorption process for the industrial isolation of immunoglobulins from whey”.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019